2019 BioHealth Capital Region Forum

Top 3 by 2023

Miss the 2019 BioHealth Capital Region Forum?


20% of the top influencers worldwide in vaccine development


World-class tech + big data + biotech + White House Precision Medicine Initiative = new frontiers in patient-centered medicine


MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

  • World–renowned research institutions and universities
  • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
  • Fastest growing region for healthcare companies in the U.S.
  • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

Founding Partners

Emmes Awarded New NIH Contracts that Address the Nation’s Opioid Addiction Crisis

October 10, 2019

The Company is Hiring Additional Staff to Support its Awards Totaling Over $9 Million ROCKVILLE, Md., Oct. 10, 2019 /PRNewswire/ — Emmes today announced the award of eight new task order contract…

Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

October 9, 2019

Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D.,…

Intralytix Opens New HQ in Columbia, Maryland for Phage Research and Manufacturing Facility

October 7, 2019

October 7, 2019 On October 4th, 2019, Intralytix officially opened its brand new 33,000 sq. ft. facility in Columbia, Maryland. The new facility is located in the Columbia Gateway Community…

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

October 7, 2019

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life…

Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors

October 4, 2019

October 04, 2019 Original Press Release GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR)…

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO

October 3, 2019

October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO Bing Yao, surrounded by colleagues and family, rang the opening Nasdaq…